Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active‐controlled, randomized, double‐blind study with open‐label extension (the EVERGREEN study)
Open Access
- 21 April 2020
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (9), 1527-1536
- https://doi.org/10.1111/dom.14061
Abstract
Aim To investigate the efficacy and safety of evogliptin compared to linagliptin in patients with type 2 diabetes mellitus (T2DM). Materials and methods In this 12‐week multicenter, randomized, double‐blind, active‐controlled, and 12‐week open‐label extension study, a total of 207 patients with T2DM who had HbA1c levels of 7.0–10.0% were randomized 1:1 to receive evogliptin 5 mg (n = 102) or linagliptin 5 mg (n = 105) daily for 12 weeks. The primary efficacy endpoint was the change from baseline HbA1c at week 12. The secondary endpoint was the change in the mean amplitude of glycemic excursion (MAGE) assessed by continuous glucose monitoring. In the extension study conducted during the following 12 weeks, evogliptin 5 mg daily was administered to both groups: evogliptin/evogliptin group (n = 95) and linagliptin/evogliptin group (n = 92). Results After 12 weeks of treatment, the mean changes in HbA1c in the evogliptin group and the linagliptin group were − 0.85% and − 0.75%, respectively. The between‐group difference was −0.10% (95% CI: −0.32 to 0.11), demonstrating non‐inferiority based on a non‐inferiority margin of 0.4%. The change in MAGE was −24.6 mg/dL in the evogliptin group and − 16.7 mg/dL in the linagliptin group. These values were significantly lower than the baseline values in both groups. However, they did not differ significantly between the two groups. In the evogliptin/evogliptin group at week 24, HbA1c decreased by −0.94%, with HbA1c values <7.0% in 80.2% of the patients. The incidence and types of adverse events were comparable between the two groups for 24 weeks. Conclusion In this study, the glucose‐lowering efficacy of evogliptin was non‐inferior to linagliptin. It was maintained at week 24 with a 0.94% reduction in HbA1c. Evogliptin therapy improved glycemic variability without causing any serious adverse events in patients with T2DM.This publication has 42 references indexed in Scilit:
- Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetesDiabetes, Obesity and Metabolism, 2013
- A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active siteBiochemical and Biophysical Research Communications, 2013
- Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trialsCardiovascular Diabetology, 2013
- Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysisDiabetes, Obesity and Metabolism, 2012
- Translating Glucose Variability Metrics into the Clinic viaContinuousGlucoseMonitoring: AGraphicalUserInterface forDiabetesEvaluation (CGM-GUIDE©)Diabetes Technology & Therapeutics, 2011
- The Loss of Postprandial Glycemic Control Precedes Stepwise Deterioration of Fasting With Worsening DiabetesDiabetes Care, 2007
- Postprandial Glucose Regulation and Diabetic ComplicationsArchives of Internal Medicine, 2004
- Plasma lipid peroxidation products and antioxidant enzyme activities in patients with type 2 diabetes mellitusActa Diabetologica, 2002
- What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo?FEBS Letters, 1997
- Day-to-day variation of continuously monitored glycaemia: A further measure of diabetic instabilityDiabetologia, 1972